Skip to Content

Dear Customer:

The current international situation is complex and volatile, and uncertain tariff policies may potentially impact our product prices. Given these uncertainties, we value your understanding regarding order-related matters.

If you decide to place an order during this period, we reserve the right to adjust the price based on the evolving situation. We understand that market changes may cause inconvenience. We will negotiate with you if there’s a significant price fluctuation due to tariff policy changes before the order’s actual delivery, and in such cases we may adjust or cancel the order as necessary.

We are planning system maintenance between Friday, Apr 18 at 9:00 PM CDT and Saturday, Apr 19 at 9:00 AM CDT. This will impact both web and offline transactions, including online orders, quotes, price and availability checks, and order status inquiries. We apologize for any inconvenience.

For important updates on recent policy changes, please click here for more details.

Merck
CN
  • JNK suppresses tumor formation via a gene-expression program mediated by ATF2.

JNK suppresses tumor formation via a gene-expression program mediated by ATF2.

Cell reports (2014-12-03)
Malgorzata Gozdecka, Stephen Lyons, Saki Kondo, Janet Taylor, Yaoyong Li, Jacek Walczynski, Gerald Thiel, Wolfgang Breitwieser, Nic Jones
ABSTRACT

JNK and p38 phosphorylate a diverse set of substrates and, consequently, can act in a context-dependent manner to either promote or inhibit tumor growth. Elucidating the functions of specific substrates of JNK and p38 is therefore critical for our understanding of these kinases in cancer. ATF2 is a phosphorylation-dependent transcription factor and substrate of both JNK and p38. Here, we show ATF2 suppresses tumor formation in an orthotopic model of liver cancer and cellular transformation in vitro. Furthermore, we find that suppression of tumorigenesis by JNK requires ATF2. We identify a transcriptional program activated by JNK via ATF2 and provide examples of JNK- and ATF2-dependent genes that block cellular transformation. Significantly, we also show that ATF2-dependent gene expression is frequently downregulated in human cancers, indicating that amelioration of JNK-ATF2-mediated suppression may be a common event during tumor development.

MATERIALS
Product Number
Brand
Product Description

Roche
Anti-Bromodeoxyuridine, from mouse IgG1 (clone: BMC9318)
Sign Into View Organizational & Contract Pricing
SKUPack SizeAvailabilityPriceQuantity
500 g
Estimated to ship on 2025年4月21日
Details...
¥227.11
100 g
Estimated to ship on 2025年4月21日
Details...
¥231.76
Sigma-Aldrich
JNK Inhibitor XI, BI-87G3, The JNK Inhibitor XI, BI-87G3, also referenced under CAS 2207-44-5, controls the biological activity of JNK. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.
Sign Into View Organizational & Contract Pricing
SKUPack SizeAvailabilityPriceQuantity
500 g
Estimated to ship on 2025年4月21日
Details...
¥227.11
100 g
Estimated to ship on 2025年4月21日
Details...
¥231.76